Archive: 25/06/2013

Immunohistochemistry effectively detects ALK rearrangement

ALK rearrangement has been demonstrated to be a potent oncogenic driver and a promising therapeutic target in non-small cell lung cancer (NSCLC). It defines a distinct molecular subset of NSCLC, in particular adenocarcinoma ...

page 4 from 9